Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast

BMC Cancer

Table 4 Factors affecting overall survival (OS) in the univariate analysis

Variables	Total no. of patients	No. of deaths	Median OS (months)	OS
				p value	Hazard ratio	95% CI for hazard ratio
Age (years)
≤45	49	8	59	-	1.00	-
>45	74	9	61	0.5251	0.74	0.3 – 1.9
T stage
T1, T2	109	5	58	-	1.00	-
T3, T4	14	12	28	< 0.0001*	33.03	5.0 – 219.0
N stage
N0, N1	63	0	58	-	1.00	-
N2, N3	60	17	51	< 0.0001*	27.97	8.7 – 89.6
M stage
M0	114	12	57	-	1.00	-
M1	9	5	52	< 0.0001*	7.03	0.9 – 55.6
ER
Positive	75	6	57	-	1.00	-
Negative	48	11	56	0.0140 ^†	3.24	1.2 – 8.7
PR
Positive	74	7	63	-	1.00	-
Negative	49	10	57	0.0748	2.34	0.9 – 6.2
HER2
Negative	82	11	56	-	1.00	-
Positive	41	6	57	0.8154	1.13	0.4 – 3.1
SUVmax
≤ 5.6	61	0	57	-	1.00	-
> 5.6	62	17	56	0.0001*	18.38	7.1 – 47.7
MTV (cm ³ )
≤ 8.55	99	7	57	-	1.00	-
> 8.55	24	10	55	< 0.0001*	7.42	2.0 – 27.0
TLG
≤ 14.43	80	7	63	-	1.00	-
> 14.43	43	10	55	0.0235 ^†	2.90	1.1 – 8.0
HF
< 0.34	99	7	57	-	1.00	-
≥ 0.34	24	10	55	< 0.0001*	7.42	2.0 – 27.0

CI = Confidence interval, ER = Estrogen receptor, PR = Progesterone receptor, OS = Overall survival, PR = Progesterone receptor, HER2 = Human epidermal growth factor receptor 2, SUVmax = Maximum standardized uptake value, MTV = Metabolic tumor volume, TLG = Total lesion glycolysis, HF = Heterogeneity factor.
*p < 0.01, ^†p < 0.05.

ISSN: 1471-2407